The Question of Morality: Understanding Traditional Values in Medical Practices
Abstract
The article analyzes the transformation of traditional values in the context of modern medical practices. The basis for the study is the unconventional concept of values, where values are considered as transcendental guidelines that exist outside the framework of social agreements. The article specifies that these guidelines are subject to constant revision under the influence of technological and social changes. The article examines in detail key medical cases, such as genome editing using the CRISPR method, pharmaceutical experiments, and the introduction of artificial intelligence in medicine. The example of He Jiankui’s experiment with genetically modified embryos illustrates the ethical and philosophical dilemmas associated with the boundaries of scientific progress. Particular attention is paid to the biopolitical context of vaccination, where medical practice becomes a symbol of solidarity and control. The role of pharmaceutical companies in shaping discourses on values is analyzed through the prism of market logic and social justice. The author shows that traditional values such as freedom, mercy, and responsibility continue to be significant, but their interpretation changes depending on the context. Special attention is paid to the dilemma of the interaction between market rationality and humanistic ideals, which is clearly manifested in the problems of accessibility of medical technologies and drugs. The article notes the need for philosophical reflection to understand values in new technological realities, offering an integrative approach that takes into account both the universal and local nature of value orientations. In conclusion, the idea is put forward that modern technologies require a new moral imperative aimed at supporting the most vulnerable social units.
Downloads
References
Ajana B. (2021) “Immunitarianism: Defence and Sacrifice in the Politics of Covid-19”, History and Philosophy of Science, vol. 43, no. 1, p. 25.
Buch V. H., Ahmed I., Maruthappu M. (2018) “Artificial Intelligence in Medicine: Current Trends and Future Possibilities”, British Journal of General Practice, vol. 68, no. 668, pp. 143–144.
CRISPR Ethical Concerns (2015) Future Work Institute (https://futureworkinstitute.com/crispr-ethical-concerns/, accessed on 05.01.2025).
“CRISPR” (2025). National Human Genome Research Institute (https://www.genome.gov/genetics-glossary/CRISPR, accessed on 05.01.2025).
“Drug Goes from $13.50 a Tablet to $750, Overnight” (2015) New York Times (https://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html, accessed on 05.01.2025).
Durkin E. (2016) “Citing EpiPen Price Hike, Clinton Touts Value-Based Pricing Plan”, InsideHealthPolicy.com’s FDA Week, vol. 22, no. 34, pp. 1–7.
Esposito R., Campbell T. (2006) “The Immunization Paradigm”, Diacritics, vol. 36, no. 2, pp. 23–48.
Foucault M. (2010) Naissance de La Biopolitique: Cours au College de France, 1978–1979, Saint Petersburg: Nauka.
Greene J. (2017) “EpiPen Controversy Reveals Complexity behind Drug Price Tags”, Annals of Emergency Medicine, vol. 69, no. 1, pp. A16–A19.
Grinkevich L. N. (2021) “Genome Editing and Regulation of Gene Expression Using CRISPR/Cas Technologies in Neurobiology”, Advances in Physiological Sciences, vol. 52, no. 3, pp. 4–23.
Halpenny G. M. (2016) “High Drug Prices Hurt Everyone”, ACS Medicinal Chemistry Letters, vol. 7, no. 6, pp. 544–546.
He Jiankui Appeared in Hong Kong to Announce the Results of His Research and Answer Questions from All Sides (2018) (https://news.sina.cn/2018-11-28/detail-ihmutuec4407821.d.html, accessed on 05.01.2025).
Kornfeldt T. (2022) The Unnatural Selection of Our Species: At the Frontier of Gene Editing, Moscow: Alpina Publisher.
Lander E. et al. (2019) “Adopt a Moratorium on Heritable Genome Editing”, Nature, no. 567, pp. 165–168.
Lee P., Bubeck S., Petro J. (2023) “Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine”, The New England Journal of Medicine, vol. 388, no. 13, pp. 1233–1239.
Liesen L. T., Walsh M. B. (2012) “The Competing Meanings of ‘Biopolitics’ in Political Science: Biological and Postmodern Approaches to Politics”, Politics and the Life Sciences, vol. 31, no. 1/2, pp. 2–15.
Light D. W., Lexchin J. (2021) “The Costs of Coronavirus Vaccines and Their Pricing”, Journal of the Royal Society of Medicine, vol. 114, no. 11, pp. 502–504.
Martonosi S. E., Behzad B., Cummings K. (2021) “Pricing the COVID-19 Vaccine: A Mathematical Approach”, Omega, no. 103, art. 102451.
Means A. J. (2022) “Foucault, Biopolitics, and the Critique of State Reason”, Educational Philosophy and Theory, vol. 54, no. 12, pp. 1968–1969.
Meloni M., Vatter M. (2023) “Biopolitics after COVID: Notes from the Crisis”, Theory & Event, vol. 26, no. 2, pp. 368–392.
Morris T. et al. (2020) “Evolution of Ethical Principles in the Practice of Pharmaceutical Medicine from a UK Perspective”, Front Pharmacol, vol. 15, no. 10, p. 1525.
Peters M. A., Besley T. (2022) “Biopolitics, Conspiracy and the Immuno-State: An Evolving Global Politico-Genetic Complex”, Educational Philosophy and Theory, vol. 54, no. 2, pp. 111–120.
Shinwari Z. K., Tanveer F., Khalil A. T. (2018) “Ethical Issues Regarding CRISPR Mediated Genome Editing”, Current Issues in Molecular Biology, no. 26, pp. 103–110.
Smith N. C. (2016) The Drug Price Dilemma. Insead Knowledge (https://knowledge.insead.edu/responsibility/drug-price-dilemma, accessed on 05.01.2025).
Souza R. F., Mathew M., Surapaneni K. M. (2023) “A Scoping Review on the Ethical Issues in the Use of CRISPR-Cas9 in the Creation of Human Disease Models”, Journal of Clinical and Diagnostic Research: JCDR, vol. 17, no. 12, pp. JE01–JE08.
“Stanford Explainer: CRISPR, Gene Editing, and beyond” (2024), Stanford University (https://news.stanford.edu/stories/2024/06/stanford-explainer-crispr-gene-editing-and-beyond, accessed on 05.01.2025).
Van Zee A. (2009) “The Promotion and Marketing of Oxycontin: Commercial Triumph, Public Health Tragedy”, American Journal of Public Health, vol. 99, no. 2, pp. 221–227.
Varkhotov Т. А. (2024) “Unconventional Nature of Value”, Patria, vol. 1, no. 1, pp. 9–29.
Yetiskin E. (2022) “Biopolitics of ‘Acquired Immunity’: The War Discourse and Feminist Response-Abilities in Art, Science, and Technology during COVID-19”, Omics: A Journal of Integrative Biology, vol. 26, no. 10, pp. 552–566.
Zhang B. et al. (2019) “Chinese Academy of Engineering Calls for Actions on the Birth of Gene-Edited Infants”, Lancet, vol. 393, iss. 10166, p. 25.